Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
J Sieper, A Deodhar, H Marzo-Ortega… - Annals of the …, 2017 - ard.bmj.com
Annals of the rheumatic diseases, 2017•ard.bmj.com
Background There is significant unmet need in patients with ankylosing spondylitis (AS) who
have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment.
Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs
and symptoms of AS in the MEASURE 2 study (NCT01649375). Methods Subjects with
active AS (N= 219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1,
2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use …
have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment.
Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs
and symptoms of AS in the MEASURE 2 study (NCT01649375). Methods Subjects with
active AS (N= 219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1,
2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use …
Background
There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375).
Methods
Subjects with active AS (N=219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use: anti-TNF-naive or inadequate response/intolerance to one anti-TNF (anti-TNF-IR). The primary endpoint was Assessment of SpondyloArthritis International Society criteria (ASAS) 20 at week 16.
Results
At week 16, 68.2% of anti-TNF-naive subjects treated with secukinumab 150 mg achieved ASAS20 compared with 31.1% treated with placebo (p<0.001). In the anti-TNF-IR group, 50.0% of subjects treated with secukinumab 150 mg achieved an ASAS20 response compared with 24.1% treated with placebo (p<0.05). Numerically greater improvements were observed with secukinumab than with placebo for most secondary endpoints. Clinical responses were sustained through week 52.
Conclusions
Secukinumab 150 mg provided sustained improvements in signs and symptoms of AS in anti-TNF-naive and anti-TNF-IR subjects through 52 weeks of therapy.
Trial registration number
NCT01649375.
ard.bmj.com
